• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Philip W. Kantoff, MD


  • Nakabayashi M, Hayes J, Taplin ME, Lefebvre P, Lafeuille MH, Pomerantz M, Sweeney C, Duh MS, Kantoff PW.Clinical predictors of survival in men with castration-resistant prostate cancer: Evidence That Gleason Score 6 Cancer Can Evolve to Lethal Disease.Cancer. 2013 Aug 15;119(16):2990-8.
  • Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Lee PA, McMahon PM.Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.Ann Intern Med. 2013 Jun 18;158(12):853-60.
  • Sun T, Wang X, He HH, Sweeney CJ, Liu SX, Brown M, Balk S, Lee GS, Kantoff PW.MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A.Oncogene. 2013 Jun 17.
  • Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, Holmberg L, Kantoff P, Konety BR, Murad MH, Penson DF, Zietman AL.Early Detection of Prostate Cancer: AUA Guideline.J Urol. 2013 May 6.
  • Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M, Van Allen E, Kryukov GV, Sboner A, Theurillat JP, Soong TD, Nickerson E, Auclair D, Tewari A, Beltran H, Onofrio RC, Boysen G, Guiducci C, Barbieri CE, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Ramos AH, Winckler W, Cipicchio M, Ardlie K, Kantoff PW, Berger MF, Gabriel SB, Golub TR, Meyerson M, Lander ES, Elemento O, Getz G, Demichelis F, Rubin MA, Garraway LA.Punctuated evolution of prostate cancer genomes.Cell. 2013 Apr 25;153(3):666-77.
  • Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW.Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial.Urology. 2013 Apr 9.
  • Schoenfeld JD, Margalit DN, Kasperzyk JL, Shui IM, Rider JR, Epstein MM, Meisner A, Kenfield SA, Martin NE, Nguyen PL, Kantoff PW, Giovannucci EL, Stampfer MJ, Mucci LA.A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer.Clin Cancer Res. 2013 Mar 15;19(6):1612-9.
  • Nakabayashi M, Xie W, Buckle G, Bubley G, Ernstoff MS, Walsh W, Morganstern DE, Kantoff PW, Taplin ME.Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.Urology. 2013 Mar;81(3):611-6.
  • Madan RA, Gulley JL, Kantoff PW.Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.Cancer J.;19(1):50-8.
  • Nam RK, Oliver TK, Vickers AJ, Thompson I, Kantoff PW, Parnes HL, Loblaw A, Roth BJ, Williams J, Temin S, Basch E.Prostate-specific antigen test for prostate cancer screening: American Society of Clinical Oncology provisional clinical opinion.J Oncol Pract. 2012 Sep;8(5):315-7.
  • Schutz FA, Pomerantz MM, Gray KP, Atkins MB, Rosenberg JE, Hirsch MS, McDermott DF, Lampron ME, Lee GS, Signoretti S, Kantoff PW, Freedman ML, Choueiri TK.Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study.Lancet Oncol. 2013 Jan;14(1):81-7.
  • Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, Montironi R, Magi-Galluzzi C, Kantoff PW, Balk SP, Liu XS, Brown M.EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.Science. 2012 Dec 14;338(6113):1465-9.
  • Choudhury AD, Kantoff PW.New agents in metastatic prostate cancer.J Natl Compr Canc Netw. 2012 Nov 1;10(11):1403-9.
  • Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS, Katz L, Subudhi SK, Anand A, Fleisher M, Kantoff PW, Oh WK.A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study.Lancet Oncol. 2012 Nov;13(11):1105-13.
  • Sonpavde G, Kantoff PW.Immunotherapy for castration-resistant prostate cancer.Urol Clin North Am. 2012 Nov;39(4):465-81.
  • Valencia PM, Pridgen EM, Perea B, Gadde S, Sweeney C, Kantoff PW, Bander NH, Lippard SJ, Langer R, Karnik R, Farokhzad OC.Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles.Nanomed. 2012 Oct 17.
  • Martin NE, Chen MH, Nguyen PL, Beard CJ, Loffredo MJ, Kantoff PW, D'Amico AV.Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade.BJU Int. 2012 Nov;110(9):1252-6.
  • Choueiri TK, Cheville J, Palescandolo E, Fay AP, Kantoff PW, Atkins MB, McKenney JK, Brown V, Lampron ME, Zhou M, Hirsch MS, Signoretti S.BRAF mutations in metanephric adenoma of the kidney.Eur Urol. 2012 Nov;62(5):917-22.
  • Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA.Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.J Natl Compr Canc Netw. 2012 Sep;10(9):1081-7.
  • Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME.Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.BJU Int. 2012 Aug 29.
  • Nguyen HC, Xie W, Yang M, Hsieh CL, Drouin S, Lee GS, Kantoff PW.Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer.Prostate. 2012 Aug 10.
  • Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY, Whitmore JB, Trager JB, Poehlein CH, Frohlich MW, Urdal DL.Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer.Cancer Immunol Immunother. 2012 Aug 3.
  • Kantoff PW, Higano CS, Small EJ, Whitmore JB, Frohlich MW, Schellhammer PF.Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.Journal of the National Cancer Institute. 2012 Jul 18;104(14):1107-9; author reply 1109-12.
  • Grisanzio C, Werner L, Takeda D, Awoyemi BC, Pomerantz MM, Yamada H, Sooriakumaran P, Robinson BD, Leung R, Schinzel AC, Mills I, Ross-Adams H, Neal DE, Kido M, Yamamoto T, Petrozziello G, Stack EC, Lis R, Kantoff PW, Loda M, Sartor O, Egawa S, Tewari AK, Hahn WC, Freedman ML.Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis.Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11252-7.
  • Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon A, Suppan C, Flavin R, Sesso H, Rider JR, Sweeney CS, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG, Giovannucci E, Ding EL, Loda M, Mucci LA.The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: a Cohort Study and Meta-analysis.Cancer Epidemiol Biomarkers Prev. 2012 Jun 26.
  • Williams SB, Hirsch MS, Kantoff PW, Richie JP.Neuroepithelial Tumor Arising in a Testicular Teratoma With Retroperitoneal Metastasis.J Clin Oncol. 2012 Jun 11.
  • Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, Park K, Kitabayashi N, MacDonald TY, Sheikh K, Vuong T, Guiducci C, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Hussain WM, Ramos AH, Winckler W, Redman MC, Ardlie K, Tewari AK, Mosquera JM, Rupp N, Wild PJ, Moch H, Morrissey C, Nelson PS, Kantoff PW, Gabriel SB, Golub TR, Meyerson M, Lander ES, Getz G, Rubin MA, Garraway LA.Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.Nat Genet. 2012 Jun;44(6):685-9.
  • Misra D, Xie W, Regan MM, Ross RW, Lee GS, Germain D, Kantoff PW, Oh WK.Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy.BJU Int. 2011 Mar 16.
  • Sun T, Mary LG, Oh WK, Freedman ML, Pomerantz M, Pienta KJ, Kantoff PW.Inherited Variants in the Chemokine CCL2 Gene and Prostate Cancer Aggressiveness in a Caucasian Cohort.Clin Cancer Res. 2011 Mar 15;17(6):1546-52.
  • Pomerantz M, Werner L, Xie W, Regan MM, Lee GS, Sun T, Evan C, Petrozziello G, Nakabayashi M, Oh WK, Kantoff PW, Freedman ML.Association of prostate cancer risk loci with disease aggressiveness and prostate cancer-specific mortality.Cancer Prev Res (Phila Pa). 2011 Mar 2.
  • Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L, Fennell T, Parkin M, Saksena G, Voet D, Ramos AH, Pugh TJ, Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie K, Baldwin J, Simons JW, Kitabayashi N, MacDonald TY, Kantoff PW, Chin L, Gabriel SB, Gerstein MB, Golub TR, Meyerson M, Tewari A, Lander ES, Getz G, Rubin MA, Garraway LA.The genomic complexity of primary human prostate cancer.Nature. 2011 Feb 10;470(7333):214-20.
  • Abe M, Xie W, Regan MM, King IB, Stampfer MJ, Kantoff PW, Oh WK, Chan JM.Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer.BJU Int. 2011 Jan;107(1):126-134.
  • Drzymalski DM, Oh WK, Werner L, Regan MM, Kantoff P, Tuli S.Predictors of survival in patients with prostate cancer and spinal metastasis. Presented at the 2009 Joint Spine Section Meeting. Clinical article.J Neurosurg Spine. 2010 Dec;13(6):789-94.
  • Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Stewart ST, Bhatnagar V, Sweeney CJ, Stahl JE, McMahon PM.Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.JAMA. 2010 Dec 1;304(21):2373-80.
  • Cho E, Curhan G, Hankinson SE, Kantoff P, Atkins MB, Stampfer M, Choueiri TK.Prospective evaluation of analgesic use and risk of renal cell cancer.J Clin Oncol..
  • Pomerantz MM, Shrestha Y, Flavin RJ, Regan MM, Penney KL, Mucci LA, Stampfer MJ, Hunter DJ, Chanock SJ, Schafer EJ, Chan JA, Tabernero J, Baselga J, Richardson AL, Loda M, Oh WK, Kantoff PW, Hahn WC, Freedman ML.Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis.PLoS Genet. 2010;6(11):e1001204.
  • Penney KL, Pyne S, Schumacher FR, Sinnott JA, Mucci LA, Kraft PL, Ma J, Oh WK, Kurth T, Kantoff PW, Giovannucci EL, Stampfer MJ, Hunter DJ, Freedman ML.Genome-Wide Association Study of Prostate Cancer Mortality.Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2869-76.
  • Sun T, Lee GS, Oh WK, Pomerantz M, Yang M, Xie W, Freedman ML, Kantoff PW.Single-Nucleotide Polymorphisms in p53 Pathway and Aggressiveness of Prostate Cancer in a Caucasian Population.Clin Cancer Res. 2010 Nov 1;16(21):5244-51.
  • Berger MF, Lawrence MS, Demichelis F, Cibulskis K, Sivachenko A, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter S, Drier Y, Ambrogio L, Fenne T, Parkin M, Gordon S, Voet D, Ramos A, Pugh T, Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie K, Baldwin J, Kitabayashi N, MacDonald TY, Kantoff PW, Gabriel SB, Gerstein MB, Golub TR, Meyerson M, Tewari A, Lander ES, Getz G, Rubin MA, Garraway LA.Characterization of complex chromosomal aberrations in primary prostate cancer genomes.Nature..
  • Oh WK, Vargas R, Jacobus S, Leitzel K, Regan MM, Hamer P, Pierce K, Brown-Shimer S, Carney W, Ali SM, Kantoff PW, Lipton A.Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients.Cancer. 2010 Sep 22.
  • Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, .Sipuleucel-T immunotherapy for castration-resistant prostate cancer.N Engl J Med. 2010 Jul 29;363(5):411-22.
  • Sun T, Lee GS, Werner L, Pomerantz M, Oh WK, Kantoff PW, Freedman ML.Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy.Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1871-8.
  • Nguyen PL, Chen MH, Beard CJ, Suh WW, Renshaw AA, Loffredo M, McMahon E, Kantoff PW, D'Amico AV.Radiation With or Without 6 Months of Androgen Suppression Therapy in Intermediate- and High-Risk Clinically Localized Prostate Cancer: A Postrandomization Analysis by Risk Group.Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1046-52.
  • Nguyen PL, Chen MH, Choueiri TK, Hoffman KE, Hu JC, Martin NE, Beard CJ, Dosoretz DE, Moran BJ, Katin MJ, Braccioforte MH, Ross R, Salenius SA, Kantoff PW, D'Amico AV.Risk of All-Cause and Prostate Cancer-Specific Mortality After Brachytherapy in Men with Small Prostate Size.Int J Radiat Oncol Biol Phys. 2010 Jun 2.
  • Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, Kantoff PW.Sipuleucel-T.Nat Rev Drug Discov. 2010 Jul;9(7):513-4.
  • Nakabayashi M, Oh WK, Jacobus S, Regan MM, Taplin ME, Kantoff PW, Rosenberg JE.Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.BJU Int. 2010 May;105(10):1392-6.
  • Penney KL, Schumacher FR, Li H, Kraft P, Morris JS, Kurth T, Mucci LA, Hunter DJ, Kantoff PW, Stampfer MJ, Ma J.A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival.Cancer Prev Res (Phila Pa). 2010 May;3(5):604-10.
  • Fiorentino M, Judson G, Penney K, Flavin R, Stark J, Fiore C, Fall K, Martin N, Ma J, Sinnott J, Giovannucci E, Stampfer M, Sesso HD, Kantoff PW, Finn S, Loda M, Mucci L.Immunohistochemical expression of BRCA1 and lethal prostate cancer.Cancer Res. 2010 Apr 15;70(8):3136-9.
  • Wang AZ, Yuet K, Zhang L, Gu FX, Huynh-Le M, Radovic-Moreno AF, Kantoff PW, Bander NH, Langer R, Farokhzad OC.ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation.Nanomed. 2010 Apr;5(3):361-8.
  • Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ.Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy.J Clin Oncol. 2010 Mar 20;28(9):1481-8.
  • Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, Perner S, Adami HO, Fall K, Mucci LA, Kantoff PW, Stampfer M, Andersson SO, Varenhorst E, Johansson JE, Gerstein MB, Golub TR, Rubin MA, Andren O.Molecular sampling of prostate cancer: a dilemma for predicting disease progression.BMC Med Genomics. 2010 Mar 16;3(1):8.
  • Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR.Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.J Clin Oncol. 2010 Mar 1;28(7):1099-105.
  • Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC.NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer.J Natl Compr Canc Netw. 2010 Feb;8(2):162-200.
  • Nguyen PL,Chen MH,Renshaw AA,Loffredo M,Kantoff PW,D'Amico AV.Survival Following Radiation and Androgen Suppression Therapy for Prostate Cancer in Healthy Older Men: Implications for Screening Recommendations.Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):337-41.
  • Nguyen PL, Chen MH, Beard CJ, Suh WW, Choueiri TK, Efstathiou JA, Hoffman KE, Loffredo M, Kantoff PW, D'Amico AV.Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence.Cancer. 2010 Feb 1;116(3):610-5.
  • Smith MR, Kantoff PW.Changes in PSA kinetics after DNA vaccine therapy-not so fast!.J Clin Oncol. 2010 Feb 1;28(4):e58; author reply e59.
  • Wo JY, Chen MH, Nguyen PL, Renshaw AA, Loffredo MJ, Kantoff PW, D'Amico AV.Evaluating the Combined Effect of Comorbidity and Prostate-Specific Antigen Kinetics on the Risk of Death in Men After Prostate-Specific Antigen Recurrence.J Clin Oncol. 2009 Dec 10;27(35):6000-5.
  • Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP.Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.Clin Cancer Res. 2009 Nov 15;15(22):7099-105.
  • Sartor O, Nakabayashi M, Taplin ME, Ross RW, Kantoff PW, Balk SP, Oh WK.Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone.Clin Genitourin Cancer. 2009 Oct;7(3):E90-2.
  • D'Amico AV,Chen MH,Renshaw AA,Loffredo M,Kantoff PW.Interval to Testosterone Recovery After Hormonal Therapy for Prostate Cancer and Risk of Death.Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):10-5.
  • Jia L, Landan G, Pomerantz M, Jaschek R, Herman P, Reich D, Yan C, Khalid O, Kantoff P, Oh W, Manak JR, Berman BP, Henderson BE, Frenkel B, Haiman CA, Freedman M, Tanay A, Coetzee GA.Functional enhancers at the gene-poor 8q24 cancer-linked locus.PLoS Genet. 2009 Aug;5(8):e1000597.
  • Sun T, Yang M, Kantoff P, Lee GS.Role of microRNA-221/-222 in cancer development and progression.Cell Cycle. 2009 Aug;8(15):2315-6.
  • Chan JM, Oh WK, Xie W, Regan MM, Stampfer MJ, King IB, Abe M, Kantoff PW.Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer.J Clin Oncol. 2009 Aug 1;27(22):3577-83.
  • Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M.Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.Cell. 2009 Jul 23;138(2):245-56.
  • Mucci LA,Stark JR,Figg WD,Schumacher F,Li H,Abe M,Hennessy K,Stampfer MJ,Gaziano JM,Ma J,Kantoff PW.Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study.Int J Cancer. 2009 Sep 1;125(5):1143-6.
  • Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava S, Freedman ML.Evaluation of the 8q24 prostate cancer risk locus and MYC expression.Cancer Res. 2009 Jul 1;69(13):5568-74.
  • Penney KL,Salinas CA,Pomerantz M,Schumacher FR,Beckwith CA,Lee GS,Oh WK,Sartor O,Ostrander EA,Kurth T,Ma J,Mucci L,Stanford JL,Kantoff PW,Hunter DJ,Stampfer MJ,Freedman ML.Evaluation of 8q24 and 17q risk loci and prostate cancer mortality.Clin Cancer Res. 2009 May 1;15(9):3223-30.
  • Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P.The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines.Cancer Res. 2009 Apr 15;69(8):3356-63.
  • Lee TH,Kantoff PW,McNaughton-Collins MF.Screening for prostate cancer.N Engl J Med. 2009 Mar 26;360(13):e18.
  • Choueiri TK,Xie W,D'Amico AV,Ross RW,Hu JC,Pomerantz M,Regan MM,Taplin ME,Kantoff PW,Sartor O,Oh WK.Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.Cancer. 2009 Mar 1;115(5):981-7.
  • D'Amico AV,Chen MH,Renshaw AA,Loffredo M,Kantoff PW.Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer.Cancer. 2008 Dec 15;113(12):3290-7.
  • Wang AZ,Bagalkot V,Vasilliou CC,Gu F,Alexis F,Zhang L,Shaikh M,Yuet K,Cima MJ,Langer R,Kantoff PW,Bander NH,Jon S,Farokhzad OC.Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy.ChemMedChem. 2008 Sep;3(9):1311-5.
  • Mucci LA,Pawitan Y,Demichelis F,Fall K,Stark JR,Adami HO,Andersson SO,Andren O,Eisenstein A,Holmberg L,Huang W,Kantoff PW,Kim R,Perner S,Stampfer MJ,Johansson JE,Rubin MA.Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort.Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1682-8.
  • D'Amico AV,Chen MH,Renshaw AA,Loffredo B,Kantoff PW.Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.J Clin Oncol. 2008 Jun 20;26(18):2979-83.
  • Tomlins S, Rhodes D, Yu J; Varambally S; Mehra R, Perner S, Demichelis F, Helgeson B, Laxman B, Morris D, Cao Q, Cao X, Andren O, Fall K; Johnson L, Wei J, Shah R, Al-Ahmadie H, Eastham J, Eggener S, Fine S, Hotakainen K, Stenman U, Tsodikov A, Gerald W, Lilja H, Reuter V, Kantoff PW, Scardino P, Rubin M, Bjartell A, Chinnaiyan A. .The Role of SPINK1 in ETS Rearrangement Negative Prostate Cancers. .Cancer Cell. 06/13/2008;6:519-28.
  • Setlur SR,Mertz KD,Hoshida Y,Demichelis F,Lupien M,Perner S,Sboner A,Pawitan Y,Andren O,Johnson LA,Tang J,Adami HO,Calza S,Chinnaiyan AM,Rhodes D,Tomlins S,Fall K,Mucci LA,Kantoff PW,Stampfer MJ,Andersson SO,Varenhorst E,Johansson JE,Brown M,Golub TR,Rubin MA.Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.Journal of the National Cancer Institute. 2008 Jun 4;100(11):815-25.
  • Halabi S,Vogelzang NJ,Kornblith AB,Ou SS,Kantoff PW,Dawson NA,Small EJ.Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.J Clin Oncol. 2008 May 20;26(15):2544-9.
  • Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O.Prostate specific antigen working group guidelines on prostate specific antigen doubling time.J Urol. 2008 Jun;179(6):2181-6.
  • Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP.A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.BJU Int. 2008 May;101(9):1084-9.
  • Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M.Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.J Clin Oncol. 2008 Mar 1;26(7):1148-59.
  • Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE Jr, Wallace ME, Kantoff PW, Carroll PR.Active surveillance for early-stage prostate cancer: review of the current literature.Cancer. 2008 Apr 15;112(8):1650-9. Review.
  • Bao BY,Chuang BF,Wang Q,Sartor O,Balk SP,Brown M,Kantoff PW,Lee GS.Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes.Prostate. 2008 Jun 1;68(8):839-48.
  • Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK.Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.Cancer. 2008 Mar 15;112(6):1247-53.
  • D'Amico AV, Halabi S, Vollmer R, Loffredo M, McMahon E, Sanford B, Archer L, Vogelzang NJ, Small EJ, Kantoff PW.p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682).Urology. 2008 May;71(5):933-7.
  • Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, Freedman M.Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.J Clin Oncol. 2008 Feb 20;26(6):842-7.
  • D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW.Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.JAMA. 2008 Jan 23;299(3):289-95.
  • Mucci LA, Pawitan Y, Demichelis F, Fall K, Stark JR, Adami HO, Andersson SO, Andrén O, Eisenstein AS, Holmberg L, Huang W, Kantoff PW, Perner S, Stampfer MJ, Johansson JE, Rubin MA.Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort.Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):249-51.
  • Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, Kantoff PW, Taplin ME, Oh WK.Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.BJU Int. 2008 Feb;101(3):308-12.
  • D'Amico AV, Kantoff PW, Chen MH.Aspirin and hormone therapy for prostate cancer.N Engl J Med. 2007 Dec 27;357(26):2737-8.
  • Corsello SM, Kantoff PW.Does androgen deprivation therapy in men with prostate cancer increase cardiovascular morbidity?.Nat Clin Pract Urol. 2008 Feb;5(2):80-1.
  • McIntyre MH, Kantoff PW, Stampfer MJ, Mucci LA, Parslow D, Li H, Gaziano JM, Abe M, Ma J.Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms.Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2233-6.
  • Keller ET, Rowley DR, Tomlins SA, Drake CG, Kantoff PW, Pienta KJ, Montie JE, Carter HB, Hruszkewicz AM, Gomez J, Mohla S, Getzenberg RH.Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy.Cancer Res. 2007 Oct 15;67(20):9613-5.
  • Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, Kantoff PW, Figlin RA, Vasconcelles MJ, Xu Y, Kufe D, Bukowski RM.Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.J Immunother. 2007 Oct;30(7):749-61.
  • Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R, Farokhzad OC.Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer.Nano Lett. 2007 Oct;7(10):3065-70.
  • Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE, Rubin MA. .TMPRSS2:ERG Gene Fusion Associated with Lethal Prostate Cancer in a Watchful Waiting Cohort.Oncogene. 07/23/2007;38(26):1-7.
  • Ross RW, Kantoff PW.Predicting outcomes in prostate cancer: how many more nomograms do we need?.J Clin Oncol. 2007 Aug 20;25(24):3563-4.
  • Mohler J, Babaian RJ, Bahnson RR, Boston B, D'Amico A, Eastham JA, Hauke RJ, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Logothetis C, MacVicar G, Pollack A, Pow-Sang JM, Roach M 3rd, Sandler H, Shrieve D, Srinivas S, Twardowski P, Urban DA, Walsh PC.Prostate cancer. Clinical practice guidelines in oncology.J Natl Compr Canc Netw. 2007 Aug;5(7):650-83.
  • Hayes JH, Barry MJ, Kantoff PW, Stahl JE.Prostate-specific antigen screening for prostate cancer: a decision-analytical perspective.BJU Int. 2007 Sep;100(3):486-8.
  • Cooperberg MR, Broering JM, Kantoff PW, Carroll PR.Contemporary trends in low risk prostate cancer: risk assessment and treatment.J Urol. 2007 Sep;178(3 Pt 2):S14-9.
  • Park Y, Downing SR, Kim D, Hahn WC, Li C, Kantoff PW, Wei LJ.Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional variable: Application to Mass Spec data.Bioinformatics. 2007 Jun 15;23(12):1451-8.
  • Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE, Rubin MA.TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.Oncogene. 2007 Jul 5;26(31):4596-9.
  • D'Amico AV, Goldhaber SZ; Chen MH, Loffredo M, RN, Renshaw AA, Loffredo B; PW Kantoff.Hormonal Therapy for Prostate Cancer and the Time Course to Cardiovascular Death.J Clin Oncol. 06/10/2007;17(25):2420-5.
  • Pomerantz MM, Freedman ML, Kantoff PW.Genetic determinants of prostate cancer risk.BJU Int. 2007 Aug;100(2):241-3.
  • Pomerantz M, Manola J, Taplin ME, Bubley G, Inman M, Lowell J, Beard C, Kantoff PW, Oh WK.Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.J Urol. 2007 Jun;177(6):2146-50.
  • Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR.Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.J Clin Oncol. 2007 Mar 20;25(9):1038-42.
  • Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright RL, Tormey L, Talcott J, Rubin MA, Loda M, Sellers WR, Richie JP, Kantoff PW, Weeks J.Development of an integrated prostate cancer research information system.Clin Genitourin Cancer. 2006 Jun;5(1):61-6.
  • Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW.Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.J Clin Oncol. 2006 Jun 20;24(18):2723-8.
  • Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R.Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6315-20.
  • Li H, Kantoff PW, Giovannucci E, Leitzmann M, Gaziano JM, Stampfer MJ, Ma J.Manganese Superoxide Dismutase (MnSOD) Polymorphism, Prediagnostic Plasma Antioxidants and Prostate Cancer Risk.Cancer Res.:In press.
  • Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW.The Prognostic Significance of Plasma Chromogranin A Levels in Hormone-Refractory Prostate Cancer Patients Treated on Cancer and Leukemia Group B (CALGB) 9480 Urology.J Am Diet Assoc.:In press.
  • George D, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW.The Prognostic Significance of Plasma Interleukin-6 (IL-6) Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer (HRCaP): Results from CALGB 9480.Clinical Cancer Research.:In press.
  • Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen K, Stampfer MJ, Willett WC, Giovannucci E.Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the PSA era.Cancer epidemiology, biomarkers & prevention.:In press.
  • Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Jacobson JO, Smith MR, Kaufman DS, Kantoff PW.A Phase I Study of estramustine, weekly docetaxel and carboplatin chemotherapy in patients with hormone refractory prostate cancer.Clinical Cancer Research.:In press.
  • Wang X,Yu J,Sreekumar A,Varambally S,Shen R,Giacherio D,Mehra R,Montie JE,Pienta KJ,Sanda MG,Kantoff PW,Rubin MA,Wei JT,Ghosh D,Chinnaiyan AM.Autoantibody signatures in prostate cancer.N Engl J Med. 2005 Sep 22;353(12):1224-35.
  • Li H, Kantoff PW, Giovannucci E, Leitzmann MF, Gaziano JM, Stampfer MJ, Ma J.Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer.Cancer Res. 2005 Mar 15;65(6):2498-504.
  • Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW.Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.Cancer. 2004 Oct 1;101(7):1569-74.
  • D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW.6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.JAMA. 2004 Aug 18;292(7):821-7.
  • Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, Xue Q, Bikoff R, Ma H, Kantoff PW, Golub TR, Loda M, Sellers WR.Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model.Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7841-6.
  • Halabi S,Small EJ,Hayes DF,Vogelzang NJ,Kantoff PW.Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583.J Clin Oncol. 2003 Feb 1;21(3):490-5.
  • Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR.Gene expression correlates of clinical prostate cancer behavior.Cancer Cell. 2002 Mar;1(2):203-9.
  • Kantoff PW, Halabi S, Farmer DA, Hayes DF, Vogelzang NA, Small EJ.Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer.J Clin Oncol. 2001 Jun 15;19(12):3025-8.
  • Kantoff PW, Halabi S, Farmer DA, Hayes DF, Vogelzang NA, Small EJ.Prognostic significance of reverse transcriptase polymerase chain reaction for prostate specific antigen in men with androgen independent prostate cancer.J Clin Oncol. 06/15/2001;12(19):2238-45.
  • Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW.Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10990-5.
  • D'Amico AV, Schultz D, Loffredo M, Dugal R, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA, Kantoff PW.Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer.JAMA. 2000 Sep 13;284(10):1280-3.
  • Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ.Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.J Clin Oncol. 1999 Aug;17(8):2506-13.
  • Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens CH, Kantoff PW.The CAG repeat within the androgen receptor gene and its relationship to prostate cancer.Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3320-3.
  • Beard CJ, Propert KJ, Rieker PP, Clark JA, Kaplan I, Kantoff PW, Talcott JA.Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: a prospective multiinstitutional outcomes study.J Clin Oncol. 1997 Jan;15(1):223-9.